Introduction
============

Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease in Western countries, affecting for instance more than 10% of all adults in the United States. NAFLD encompasses a wide spectrum of different stages, ranging from steatosis with normal hepatic function to nonalcoholic steatohepatitis (NASH) and further to cirrhotic NASH and even hepatocellular carcinoma (for review see ([@bib1])). Several endocrine pathways are known to contribute to the development and progression of NAFLD ([@bib2]), including thyroid hormone (TH). A strong connection between systemic hypothyroidism and NAFLD has been established in humans ([@bib3], [@bib4], [@bib5]) and rodents ([@bib6]). Even in the euthryoid range, a link between NAFLD and higher free 3,3′,5-triiodothyronine (fT3) and lower free thyroxine (fT4) levels has been described ([@bib7]); however, the negative correlations of NAFLD with fT3 and fT4 in these euthyroid subjects suggest that the local hepatic levels of TH might be of even greater relevance for the disease pathogenesis than the systemic TH levels. In fact, a previous study on a small cohort in patients with NAFLD has found increased expression of the TH-inactivating enzyme deiodinase type 3 (DIO3) in human liver biopsies ([@bib8]), suggesting that intracellular TH action might be reduced in this condition ([@bib9]).

These findings fit well to the emerging concept that the levels of TH in the cell or organ might differ substantially from their concentrations in the circulation due to several cellular gatekeeping mechanisms. These mechanisms control for instance the entry of the hormone into the target cell through specific TH transport proteins such as MCT8 (monocarboxylate transporter 8, SLC16A2), MCT10 (SLC16A10) or OATP1C1 (organic anion transporting polypeptide 1c1, SLCO1C1), which have distinct and different expression patterns throughout the body ([@bib10]). As a second step, intracellular deiodinase enzymes catalyze the conversion of THs, thus governing the activation (DIO1 and DIO2) or inactivation (DIO1 and DIO3) of the active hormone 3,3′,5-triiodothyronine (T3) and its precursor 3,3′,5,5′-tetraiodothyronine (thyroxine, T4). Finally, two different genes exist for nuclear TH receptors, *THRA* coding for TRα1 and *THRB* for TRβ, which mediate the genomic effects of the hormone and stimulate or repress gene expression in target cells. With regard to the liver, it is well established that these gatekeeping mechanisms are predominantly governed by DIO1 and TRβ, while the role of the different transport proteins is less clear ([@bib11]).

Targeting hepatic TH signaling has been a longterm goal in the field, evidenced by the ample number of TRβ-specific compound such as GC-1, GC-24, KB141, KB2115 or MB07811 ([@bib12], [@bib13], [@bib14], [@bib15]). Despite their encouraging potential to induce favorable metabolic effects including lowering cholesterol levels, significant off-target effects were discovered during clinical trials (for review see ([@bib16])). Moreover, it was suggested that their liver-specific effect might be a consequence of transporter rather than TRβ specificity ([@bib17]). However, most recently it was shown that a low-dose TH treatment is effective to reduce hepatic lipid content in NAFLD patients ([@bib18]), underlining the great potential of TH in the treatment of the disease. Unfortunately, to date, little is known regarding the different gatekeeping mechanisms for TH action in the human liver and alterations that occur during NAFLD, which could affect therapeutic strategies to target hepatic TH signaling in this condition. To test this hypothesis, we here investigate the expression of TH transporters, deiodinases and receptors in a unique collection of human liver biopsies from patients with different stages of NASH.

Materials and methods
=====================

Study design and patients
-------------------------

To establish a tissue bank for metabolic disorders, liver wedge biopsies were obtained in a standardized fashion from segment III during bariatric surgery of obese subjects at University Hospital Eppendorf (UKE, Hamburg). All participants signed an informed consent. The study was approved by the local ethics committee 'Ethik Komission der Ärztekammer Hamburg' (PV4889, 2015). As this was no direct recruitment for a study, the cohort is not matched for age and gender. Therefore, age and gender were tested as possible confounding factors and the results were corrected if necessary. NAFLD activity score was determined according to the current recommendations ([@bib19]) by two expert pathologists. The patients were fasted for 6 h prior surgery, but had no dietary restrictions otherwise. Clinical parameters were measured at the time of the surgery by the Institut für Klinische Chemie und Laboratoriumsmedizin, Zentrum für Diagnostik, Universitätsklinikum Eppendorf, Hamburg, Germany according to the DIN EN ISO 15189:2014 certification. Glucose, cholesterol, HDL and triglycerides were determined using photometric assays, HbA1c was quantified using capillary electrophoresis or turbidimetric inhibition assays and folic acid and TSH were measured using luminescent oxygen channeling immunoassays (LOCI). The intra- and interassay variance for the TSH LOCI assay are typically in the range of 2.1 and 17% respectively ([@bib20]). Total T3 and T4 were determined from frozen serum samples using ELISAs (EIA-1781, DRG Diagnostics, Germany for T4 and DNOV053, NovaTec Immundiagnostica GmbH, Germany).

RNA isolation and gene expression measurement by qPCR
-----------------------------------------------------

Whole-cell RNA was extracted from approximately 25 mg of snap frozen liver using the MiRNeasy mini kit (QIAGEN) as indicated by the manufacturer and quantified spectrometrically. Two micrograms of RNA were reverse transcribed into cDNA using the SuperScript VILO cDNA synthesis kit (Invitrogen). Gene expression was measured by qPCR using FastStart Universal SYBR Green (Roche) and 0.25 µM of each primer (sequences are available on request). The efficiency of all qPCR reactions was similar and above 95%. Absence of genomic DNA was confirmed in a reaction without reverse transcriptase. Relative gene expression was calculated with the ΔΔCt method. Thirty-one potential housekeeping genes were tested with TaqMan Array Human Controls Plate (Applied Biosystems). According to the NormFinder algorithm ([@bib21]), *CASC3* was the best housekeeping gene and therefore all expression data were normalized to *CASC3* expression. ΔCt values were normalized to a 0--1 scale by 1 − (xi − min(x))/(max(x) − min(x))) for the visualization of gene expression, indicating 0 as lowest measured expression and 1 as highest measured expression.

Statistics
----------

Correlations between gene expression (using ΔCt values) and the possible confounding factors were analyzed by Pearson's correlation for continuous parameters (age) and Spearman correlation as well as Student's *t*-test for ordinal parameters (gender), according to the *Handbook of Biological Statistics* ([@bib22]). As *DIO1* and *THRB* were affected by age and *SLC16A2* by gender, all subsequent *P* values and effect sizes for these genes were corrected for age or gender respectively using a linear regression model. The respective figures contain the *P* values calculated by Pearson's correlation for continuous parameters (TSH, serum triglycerides, HbA1c, blood glucose) or Spearman correlation for ordinal parameters (NASH score), as well as the age/gender corrected *P* values derived from the linear regression model. All statistic calculations were performed by MATLAB, version R2016a (The MathWorks). Table 1Characteristics of the human patient cohort.ParameterUnitMeanSt. DevMinMax*n*Genderm/f24/6185Ageyears43.812.8227285BMIkg/m^2^52.210.832.284.985TSH^a^mU/L2.55.00.145.780T3ng/mL0.90.20.11.376T4µg/dL5.41.32.79.176Triglyceridesmmol/L2121215761185Total cholesterolmg/dL1884110936785LDLmg/dL101341217479HbA1c%6.51.94.311.885Blood glucosemg/dL130647536785Diabetes^b^Diagnosed yes/no34/5185HypertoniaDiagnosed yes/no52/3183NAFLD activityScore2.82.20673NAS frequencyScore (number)0 (19), 1 (5), 2 (10), 3 (8), 4 (10), 5 (12), 6 (9)FibrosisFib-4 score0.80.60.22.784FibrosisDiagnosed yes/no39/4584[^1] Table 2Detailed statistical analyses of the correlations in the study.*P* value Pearson*P* value Spearmann*P* value correctedCorrelation coefficientEffect sizeEffect size corrected*n*Age DIO10.0241\*−0.25535.229878 SLC10A10.3516−0.103583 SLC16A20.0827−0.194081 THRA0.72670.039481 THRB0.0392\*−0.22827.918682Gender DIO10.43050.090578 SLC10A10.07700.195283 SLC16A20.0317\*0.238981 THRA0.48360.078981 THRB0.74390.036682BMI DIO10.7884−0.030978 SLC10A10.9574−0.005983 SLC16A20.68790.045381 THRA0.62610.054981 THRB0.28270.120082TSH DIO10.77780.9858−0.033474 SLC10A10.46010.084379 SLC16A20.31590.42750.115877 THRA0.9453−0.008077 THRB0.70880.53560.043078T3 DIO10.87830.89200.018869 SLC10A10.9815−0.002873 SLC16A20.56040.9793−0.069772 THRA0.7431−0.039671 THRB0.15900.25480.166673T4 DIO10.27470.8059−0.133469 SLC10A10.8695−0.019474 SLC16A20.24700.3490−0.137273 THRA0.4991−0.080972 THRB0.29490.5051−0.123474Serum triglycerides DIO10.00970.0706−0.291259.34578 SLC10A10.0611−0.206583 SLC16A20.02830.0833−0.243756.01481 THRA0.85730.020381 THRB0.00240.0175\*−0.3303110.3381.40182HbA1c DIO10.00410.0434\*−0.32180.98490.630578 SLC10A10.9033−0.013583 SLC16A20.07590.1557−0.198381 THRA0.58010.062481 THRB0.00300.0268\*−0.32361.66211.104982Blood glucose DIO10.09170.4940−0.192378 SLC10A10.8022−0.027983 SLC16A20.07050.1653−0.202181 THRA0.66210.049381 THRB0.01140.0843−0.278047.881082NASH score DIO10.29080.5044−0.130069 SLC10A10.86630.020274 SLC16A20.75560.7036−0.037972 THRA0.54480.072574 THRB0.00840.0461\*−0.310671[^2]

Results
=======

As TH signaling has been connected to NASH development and progression, we hypothesized that the local control of TH levels might be pathologically altered in livers of patients with different stages of NASH. We therefore tested the expression of TH transporters, deiodinases and receptors in a unique collection of human liver biopsies ([Table 1](#tbl1){ref-type="table"}). Our data showed strong expression of both TH receptors, *SLC16A2*, *SLC10A1* and *DIO1*, whereas the mRNA levels of *SLCO1C1*, *DIO2* and *DIO3* were more than 10-fold lower, suggesting negligible biological relevance ([Fig. 1A](#fig1){ref-type="fig"}). As the cohort was controlled for BMI, but not for age and gender, we tested these two factors as possible confounders, revealing that the hepatic expression of *SLC16A2* was significantly higher in females than in males ([Fig. 1A](#fig1){ref-type="fig"}, correlation *P* = 0.0317, *t*-test *P* = 0.0264), and *DIO1* and *THRB* mRNA levels declined significantly with age ([Fig. 1B](#fig1){ref-type="fig"}, *P* = 0.0241 for *DIO1* and *P* = 0.0392 for *THRB*). Remarkably, none of the genes were significantly correlated with serum levels of thyroid-stimulating hormone (TSH) or serum T3 or T4 concentrations ([Table 2](#tbl2){ref-type="table"}); however, almost all patients were in the euthyroid range. Interestingly, one patient was severely hypothyroid, but had inconspicuous *DIO1* mRNA expression ([Fig. 1C](#fig1){ref-type="fig"} and Supplementary Fig. 1A, see section on [supplementary data](#supp1){ref-type="supplementary-material"} given at the end of this article).Figure 1(A) Gene expression of thyroid hormone receptors, transporters and deiodinases in human liver biopsies of males and females, depicted as delta Ct to the housekeeping gene *CASC3* with high expression levels on the left. (B) Correlation of NTCP (*SLC10A1*), MCT8 (*SLC16A2*), thyroid hormone receptor α and β (*THRA* and *THRB*) and deiodinase type I (*DIO1*) mRNA expression with age. (C) Correlation of deiodinase type I (*DIO1*) mRNA expression with serum thyroid stimulating hormone (TSH).

We then tested whether the expression was correlated to systemic markers of lipid metabolism, revealing that *SLC16A2*, *DIO1* and *THRB* were negatively correlated with serum triglyceride levels, while *SLC10A1* and *THRA* were not affected ([Fig. 2A](#fig2){ref-type="fig"} and Supplementary Fig. 1B). However, when the respective confounding factors were used for correction, only the expression of *THRB* remained significantly correlated (*P* ~a~ = 0.0175). No correlation to LDL or total cholesterol was observed (data not shown). With regard to markers of glucose metabolism, hepatic *DIO1* and *THRB* mRNA expression were negatively associated with HbA1c ([Fig. 2B](#fig2){ref-type="fig"} and Supplementary Fig. 1C), even after correction for age (*P* ~a~ = 0.0434 for *DIO1* and *P* ~a~ = 0.0268 for *THRB*). No association for any of the genes was observed with blood glucose concentrations (data not shown), except for *THRB*, which however was not significant after correction for age (Supplementary Fig. 1C).Figure 2(A) Correlation of MCT8 (*SLC16A2*), deiodinase type I (*DIO1*) and thyroid hormone receptor β (*THRB*) mRNA expression with serum triglyceride levels. (B) Correlation of MCT8 (*SLC16A2*), deiodinase type I (*DIO1*) and thyroid hormone receptor β (*THRB*) mRNA expression with glycated haemoglobulin A1c (HbA1c). The respective raw and corrected *P*-values for age (a) or gender (g) are given in the figures.

Finally, we tested for an association of NASH score with the respective genes. The analysis revealed that *THRB* mRNA expression was negatively associated with NASH score (*P* = 0.0084, after correction for age *P* ~a~ = 0.0461), with lower expression in higher stages ([Fig. 3A](#fig3){ref-type="fig"}), while the other genes were not correlated (Supplementary Fig. 2A). The expression of *THRB* mRNA was also not correlated with APOF mRNA levels (Supplementary Fig. 2B), a molecular marker of fibrosis ([@bib23]). Taken together, the data indicate that reduced *THRB* expression, which further declines with age, is connected to more progressed stages of NASH ([Fig. 3B](#fig3){ref-type="fig"}) and suggest an altered cellular responsiveness to TH during disease progression and aging ([Fig. 3C](#fig3){ref-type="fig"}).Figure 3(A) Correlation of thyroid hormone receptor β (*THRB*) mRNA expression with NASH score. The respective raw *P* value and corrected for age (a) are given in the figure. (B) 3D model of the correlations between NASH score and age as well as *THRB* mRNA expression with the respective raw and corrected *P* values. (C) Schematic overview of the changes in liver cell thyroid hormone economy with age and NASH. DIO, deiodinase; MCT8, SLC16A2; NTCP, SLC10A1; rT3, 3,3′,5′-triiodothyronine; SLCO1C1, OATP1C1; T3, 3,3′,5-triiodothyronine; T4, thyroxine; TR, thyroid hormone receptor.

Discussion
==========

Our study is the first to comprehensively test the expression of genes gating local TH action in liver, including transporters, deiodinases and receptors in NAFLD patients. As liver samples cannot be obtained from healthy individuals due to ethical reasons (due to the risk associated with a liver biopsy), our cohort is naturally limited to sick individuals, in this case exhibiting severe obesity requiring bariatric surgery. Consequently, the results cannot be compared to a healthy control group, but were used to correlate gene expression with the severity of NAFLD, i.e. NAFLD activity score. Therefore, the results might not be representative for NAFLD patients in general, but given that obesity is the major risk factor for NAFLD ([@bib24]), the findings are still of clinical relevance. Moreover, our results are currently limited to the mRNA expression; unfortunately, however, to the best of our knowledge reliable and properly validated commercial antibodies for TH receptors, deiodinases or transporters are currently not available ([@bib25]).

Hepatic gene expression in human liver
--------------------------------------

As local changes in TH economy are expected in livers of patients with NAFLD ([@bib9]), we tested the expression of the relevant genes in our biopsy collection. As expected, we could not detect *SLCO1C1*, *DIO2* and *DIO3* transcripts. DIO3 has been described in human fetal liver and adult livers of critically ill patients, but in line with our findings, it was reported to be absent in healthy adult human liver samples ([@bib26], [@bib27]). We identified hepatic expression of both TH receptor genes, which was not correlated to serum TSH, corroborating previous findings ([@bib28]). Surprisingly, we did not find any correlation of *DIO1* with serum TSH, T4 or T3, although the gene is known as a sensitive marker of peripheral TH status in the mouse ([@bib29]) and also positively correlated with T3 in critically ill patients on enzyme and transcript level ([@bib30]). However, only two patients in our cohort were outside the euthyroid reference range with TSH concentrations of 0.08 mU/L and 45.7 mU/L respectively, but their *DIO1* transcript levels were not obviously altered. Interestingly, however, we observed lower *DIO1* transcripts levels correlating with elevated HbA1c as long-term marker for diabetes, which concurs with previous animal studies showing low T3 and lower outer ring deiodination activity in type I diabetic rats ([@bib31]) and mice ([@bib32]). With regard to TH transporters, we observed a slightly higher expression of *SLC16A2* (MCT8) in female individuals, potentially due to the fact that it is an X-chromosomal gene ([@bib10]).

Effects of aging
----------------

In the general population, decreased thyroid function is associated with longevity ([@bib33]). Moreover, older adults show a prevalence for subclinical hypothyroidism, but it is currently highly controversial whether a treatment is beneficial or harmful ([@bib34]). Consequently, data on the local change in TH economy on the tissue level are highly relevant to understand the underlying causes and therapeutic consequences. Several studies on animal models are available, revealing decreased liver *Slc16a2* and *Dio1* expression in old rats ([@bib35]), increased *Slc10a1* but unaltered *Slc16a2* transcripts in old mice ([@bib36]) and lower DIO1 activities in several mouse models of aging ([@bib37]). On the receptor level, no effect of age on *Thra* was observed, while a progressive increase in *Thrb* mRNA and total TRβ protein level was found in old rats; however, most remarkably, the nuclear levels of TRβ seemed to decline ([@bib35]). Data on the human situation are scarce, reporting only an age-dependent decrease in *THRB* expression in peripheral blood mononuclear cells, presumably driven by changes in promoter methylation ([@bib38]). Consequently, our data on decreased hepatic *THRB* and *DIO1* expression are of explicit biological relevance for the understanding of TH economy in the aging liver, as they suggest that the liver might become somewhat resistant to circulating TH.

Nonalcoholic steatohepatitis
----------------------------

Hypothyroidism is a known risk factor for NAFLD; however, the underlying mechanisms are complex likely involving a combination of direct hepatic effects and indirect actions via adipocytes ([@bib39]). The role of hepatic deiodination in this context is controversial: some suggested a higher conversion of T4 as evidenced by an elevated T3/T4 ratio in patients with NAFLD ([@bib40]), while others observed increased DIO3 and reduced DIO1 in NAFLD using immunohistochemistry on a small number of liver biopsies ([@bib8]). However, our data from a larger cohort now suggest that at least the mRNA levels of *DIO1* do not change over the course of the disease, while we could also not detect unusual expression of the other deiodinases.

That the expression of *THRB* decreases with higher stages of NASH is a potentially relevant finding, raising several questions for follow-up studies. Most importantly, using single-cell sequencing, it needs to be established whether the number of cells expressing *THRB* is reduced or whether our results represent an overall reduction in *THRB* expression. This could have clinical implications for the validity of *THRB* expression as additional parameter to determine the NASH score on the molecular level. Secondly, it needs to be tested, whether the lower transcript levels are a consequence of the disorder, for example, through the suppressing effect of higher serum triglyceride levels or whether they could be causally involved in NASH development. For this, one would first need to establish whether the observed amount of reduction in *THRB* mRNA translates to reduced protein levels and cellular resistance to TH. However, it is tempting to speculate that NASH progression and declining *THRB* expression jointly initiate a viscious cycle, which could be broken by (re)activation of hepatic TH signaling. This has been tried for a long time using TRβ selective compounds; unfortunately, to date, with little success due to severe side effects ([@bib16]). More promising results have been obtained more recently with a liver targeted glucagon-T3 ([@bib41]) or a low-dose T4 treatment in NAFLD patients ([@bib18]). However, our data indicate that the efficiency of these approaches might depend on the stage of the disease, since at a certain point the cellular resistance might be irreversible due to the lack of reactivatable TRβ.
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[^1]: ^a^16 of which are treated with thyroxine. ^b^30 of which are treated with insulin and/or metformin.

[^2]: As DIO1 and THRB as dependent variables were found to be significantly affected by age, all subsequent correlations of these genes were corrected for age. Likewise, SLC16A2 was significantly affected by gender; hence, the subsequent analyses for this gene were corrected for gender. \*: *P* \< 0.05
